Pharmaceutical Business review - Page 316 of 5221 -

Haematology

September 26, 2024

MITEM PHARMA acquires global rights to injectable medicine from Novartis

French pharmaceutical company MITEM PHARMA has announced the acquisition of worldwide rights to DESFERAL (deferoxamine), an injectable medicine of major therapeutic interest (MITM) in haematology field, from Novartis.

Continue

MITEM PHARMA’s strategy involves identifying therapeutic needs, ensuring the supply and availability of existing medicines. Credit: Sam Moghadam Khamseh on Unsplash.

Deals

PRESS RELEASES

Whitepapers

Drug Discovery

Research & Development

FDA grants fast track designation for Elevation Oncology’s EO-3021

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Clinical Trials

Patient Enrollment

US FDA approves Avacta Group’s IND application for AVA6000

AM-Pharma enrols first patients in Covid-19 phase III trial

Regulation

Drug Filing

FDA grants priority review for Bavarian Nordic’s chikungunya vaccine BLA

FDA accepts Exelixis’ cabozantinib sNDA for neuroendocrine tumours

Production & Sales

Manufacturing

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Merck introduces single-use reactor to accelerate ADC manufacturing

Packaging & Supply Chain

Packaging

Gerresheimer

PCI Pharma announces bottling line expansion at Rockford site

Suppliers

No data found

MITEM PHARMA acquires global rights to injectable medicine from Novartis

Amgen’s TEPEZZA gets Japan’s MHLW approval for thyroid eye disease treatment

FDA grants fast track designation for Elevation Oncology’s EO-3021

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Harbour BioMed, Moderna partner on immunotherapies development

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Q32 Bio concludes merger deal with Homology Medicines

Zuellig Pharma acquires Cialis and Alimta brands from Lilly

Popular

Pharmaceutical Business review is using cookies